2012 Scrip 100 Preview: Base jumping for pharma – a slower descent from the patent cliff?
This article was originally published in Scrip
Executive Summary
If there is one fact that even the most casual observer of the pharma industry is aware of, it is that there is a patent cliff, and many companies in the process of falling off it! The latest numbers suggest that brands generating more than $150 billion in global sales in 2010 will lose primary patent protection in at least one major market by 2015.